美泊利单抗联合或不联合FESS对CRSwNP2型炎症的长期影响
这项RCT纳入58例重度CRSwNP患者,比较美泊利单抗单用或联合FESS对上下气道炎症、肺功能及症状的影响。两组FEV1%、FVC%、炎症标志物及患者报告结局均改善,联合FESS在鼻息肉评分和鼻塞等症状上获益更大,但下气道炎症改善两组相似。
要点
- 美泊利单抗可改善CRSwNP患者上下气道结局。
- 联合FESS额外改善鼻息肉评分和鼻部症状负担。
- FESS未进一步影响下气道炎症。
核心结论
- 美泊利单抗改善CRSwNP患者上下气道结局,FESS增加鼻窦症状控制的局部获益但不进一步影响下气道炎症。
研究设计与样本
- RCT,58例重度CRSwNP患者接受美泊利单抗单用或联合FESS,按基线炎症亚组分层,在基线、6个月和12个月分析血、鼻和支气管炎症及症状结局。
主要发现
- 两组FEV1%均改善(MepoFESS:+3.4%,p=0.010;Mepo Only:+3.5%,p=0.015)。
- 两组FVC%均改善(MepoFESS:+3.7%,p<0.001;Mepo Only:+2.9%,p=0.009)。
- 两组FeNO、血嗜酸性粒细胞、鼻息肉嗜酸性粒细胞及所有患者报告结局均改善。
- MepoFESS在鼻息肉评分、鼻塞和总体症状负担上获益更大。
- 两组肺功能和全身炎症改善相似。
临床怎么用
- 对重度CRSwNP伴或不伴哮喘患者,可考虑美泊利单抗改善上下气道结局。
- 联合FESS可额外改善鼻息肉和鼻部症状,但不应期望进一步改善下气道炎症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti-IL-5 therapy, treats conditions systemically, while functional endoscopic sinus surgery (FESS) primarily addresses sinonasal disease and can improve asthma control. The combined effect on airway outcomes remains unclear. This study evaluated the global airway hypothesis with objective measures and targeted therapies. OBJECTIVE: To investigate the impact of mepolizumab, with or without FESS, on airway inflammation, lung function, and symptom burden in severe CRSwNP with or without asthma. METHODS: In this RCT, 58 patients received either mepolizumab alone or combined with FESS. Inflammation and symptom outcomes were analyzed in blood, nose, and bronchi at baseline, six, and 12 months. Patients were stratified by baseline inflammatory subgroup. RESULTS: Both groups showed improvements in FEV1% (MepoFESS: +3.4%, p = 0.010; Mepo Only: +3.5%, p = 0.015), FVC% (MepoFESS: +3.7%, p < 0.001; Mepo Only: +2.9%, p = 0.009), inflammation markers (FeNO, blood eosinophils, nasal polyp eosinophils), and all patient-reported outcomes. MepoFESS produced greater gains in nasal polyp score, nasal congestion, and overall symptom burden. Lung function and systemic inflammation improved similarly in both groups. CONCLUSIONS: Mepolizumab improves upper and lower airway outcomes in CRSwNP. FESS adds localized benefits in sinonasal symptom control without further impact on lower airway inflammation. Findings support a comprehensive approach targeting systemic and local type 2 inflammation in global airway disease.
引用
- Tidemandsen J, Backer V, Homøe AS, et al. The Global Airways in Practice: Long-term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP. Int Forum Allergy Rhinol. 2025. PMID: 41395863. doi:10.1002/alr.70073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。